150 related articles for article (PubMed ID: 24310589)
1. The influence of formulation and manufacturing process parameters on the characteristics of lyophilized orally disintegrating tablets.
Jones RJ; Rajabi-Siahboomi A; Levina M; Perrie Y; Mohammed AR
Pharmaceutics; 2011 Jul; 3(3):440-57. PubMed ID: 24310589
[TBL] [Abstract][Full Text] [Related]
2. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
3. Application of Texture Analysis Technique in Formulation Development of Lyophilized Orally Disintegrating Tablets Containing Mannitol, Polyvinylpyrrolidone and Amino Acids.
Hackl E; Ermolina I
AAPS PharmSciTech; 2019 Jan; 20(2):71. PubMed ID: 30631978
[TBL] [Abstract][Full Text] [Related]
4. An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.
Hobbs D; Karagianis J; Treuer T; Raskin J
Drugs R D; 2013 Dec; 13(4):281-8. PubMed ID: 24170256
[TBL] [Abstract][Full Text] [Related]
5. Development and optimization of lyophilized orally disintegrating tablets using factorial design.
Ahmed IS; Shamma RN; Shoukri RA
Pharm Dev Technol; 2013; 18(4):935-43. PubMed ID: 22107175
[TBL] [Abstract][Full Text] [Related]
6. Exploring the performance-controlling tablet disintegration mechanisms for direct compression formulations.
Maclean N; Walsh E; Soundaranathan M; Khadra I; Mann J; Williams H; Markl D
Int J Pharm; 2021 Apr; 599():120221. PubMed ID: 33540006
[TBL] [Abstract][Full Text] [Related]
7. Formulation study for orally disintegrating tablet using partly pregelatinized starch binder.
Mimura K; Kanada K; Uchida S; Yamada M; Namiki N
Chem Pharm Bull (Tokyo); 2011; 59(8):959-64. PubMed ID: 21804239
[TBL] [Abstract][Full Text] [Related]
8. Amorphous Formulation and in Vitro Performance Testing of Instantly Disintegrating Buccal Tablets for the Emergency Delivery of Naloxone.
Alqurshi A; Kumar Z; McDonald R; Strang J; Buanz A; Ahmed S; Allen E; Cameron P; Rickard JA; Sandhu V; Holt C; Stansfield R; Taylor D; Forbes B; Royall PG
Mol Pharm; 2016 May; 13(5):1688-98. PubMed ID: 26977787
[TBL] [Abstract][Full Text] [Related]
9. Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents.
AlHusban F; Perrie Y; Mohammed AR
Eur J Pharm Biopharm; 2010 Jun; 75(2):254-62. PubMed ID: 20332027
[TBL] [Abstract][Full Text] [Related]
10. Maltodextrin: a novel excipient used in sugar-based orally disintegrating tablets and phase transition process.
Elnaggar YS; El-Massik MA; Abdallah OY; Ebian AE
AAPS PharmSciTech; 2010 Jun; 11(2):645-51. PubMed ID: 20405257
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Optimization of Fast-Disintegrating Tablet Containing Naratriptan Hydrochloride Using D-Optimal Mixture Design.
Omar SM; AbdAlla FI; Abdelgawad NM
AAPS PharmSciTech; 2018 Aug; 19(6):2472-2487. PubMed ID: 29869307
[TBL] [Abstract][Full Text] [Related]
12. Application of polyvinyl acetate in an innovative formulation strategy for lyophilized orally disintegrating tablets.
Vanbillemont B; De Beer T
Int J Pharm; 2020 Oct; 588():119717. PubMed ID: 32771503
[TBL] [Abstract][Full Text] [Related]
13. Effect of processing methods on xylitol-starch base co-processed adjuvant for orally disintegrating tablet application.
Bin LK; Helaluddin ABM; Islam Sarker MZ; Mandal UK; Gaurav A
Pak J Pharm Sci; 2020 Mar; 33(2):551-559. PubMed ID: 32276897
[TBL] [Abstract][Full Text] [Related]
14. Formulation studies for mirtazapine orally disintegrating tablets.
Yıldız S; Aytekin E; Yavuz B; Bozdağ Pehlivan S; Ünlü N
Drug Dev Ind Pharm; 2016; 42(6):1008-17. PubMed ID: 26530146
[TBL] [Abstract][Full Text] [Related]
15. A prediction model based on artificial intelligence techniques for disintegration time and hardness of fast disintegrating tablets in pre-formulation tests.
Momeni M; Afkanpour M; Rakhshani S; Mehrabian A; Tabesh H
BMC Med Inform Decis Mak; 2024 Mar; 24(1):88. PubMed ID: 38539201
[TBL] [Abstract][Full Text] [Related]
16. Formulation of multiparticulate systems as lyophilised orally disintegrating tablets.
Alhusban F; Perrie Y; Mohammed AR
Eur J Pharm Biopharm; 2011 Nov; 79(3):627-34. PubMed ID: 21693189
[TBL] [Abstract][Full Text] [Related]
17. Orally disintegrating tablet of novel salt of antiepileptic drug: formulation strategy and evaluation.
Rahman Z; Siddiqui A; Khan MA
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1300-9. PubMed ID: 23800704
[TBL] [Abstract][Full Text] [Related]
18. Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression.
Olmez SS; Vural I; Sahin S; Ertugrul A; Capan Y
Pharmazie; 2013 Feb; 68(2):110-6. PubMed ID: 23469682
[TBL] [Abstract][Full Text] [Related]
19. Stability of freeze-dried tablets at different relative humidities.
Corveleyn S; Remon JP
Drug Dev Ind Pharm; 1999 Sep; 25(9):1005-13. PubMed ID: 10518240
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets.
Shoukri RA; Ahmed IS; Shamma RN
Eur J Pharm Biopharm; 2009 Sep; 73(1):162-71. PubMed ID: 19406232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
